clonidine has been researched along with Cardiovascular Diseases in 22 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
Excerpt | Relevance | Reference |
---|---|---|
"The incidence of perioperative myocardial ischemia was significantly reduced with clonidine (intraoperative and postoperative, 18 of 125, 14% vs." | 5.11 | Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery. ( Boisvert, DM; Galindez, D; Haratonik, KA; Kardatzke, D; Layug, EL; Lazo, EA; Salahieh, A; Wallace, AW, 2004) |
"As clonidine has been associated with cardiovascular adverse effects, it should be administered only in cases where blood pressure regulation is mandatory." | 2.61 | Non-Hormonal Replacement Therapy Regimens: Do they have an Effect on Cardiovascular Risk? ( Ampatzi, C; Goulis, DG; Mareti, E; Paschou, SA; Voziki, E, 2019) |
" While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs." | 2.49 | Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. ( Banaschewski, T; Buitelaar, J; Coghill, D; Cortese, S; Danckaerts, M; Dittmann, RW; Graham, J; Holtmann, M; Sergeant, J; Taylor, E, 2013) |
"As clonidine is a well-known effector of the autonomous system, stimulating vagal tone and decreasing sympathetic activity, we compared the autonomous reactions of children with constitutional growth delay (CGD), growth hormone deficiency (GHD) and former small for gestational age (SGA)." | 1.42 | Modified Clonidine Testing for Growth Hormone Stimulation Reveals α2-Adrenoreceptor Sub Sensitivity in Children with Idiopathic Growth Hormone Deficiency. ( Buchhorn, R; Meint, S; Rager, K; Willaschek, C, 2015) |
"Treatment with tizanidine was effective in 60% of the patients; there were high correlations between spasticity before and after tizanidine administration and the severity of symptoms and also between the degree of improvement in spasticity and in that of the symptoms." | 1.28 | Development of a simple spasticity quantification method: effects of tizanidine on spasticity in patients with sequelae of cerebrovascular disease. ( Asanuma, M; Hirata, H; Ogawa, N; Ota, Z; Yamamoto, M; Yamawaki, Y, 1992) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 8 (36.36) | 18.7374 |
1990's | 4 (18.18) | 18.2507 |
2000's | 2 (9.09) | 29.6817 |
2010's | 8 (36.36) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Oyama, JI | 1 |
Node, K | 1 |
Mareti, E | 1 |
Ampatzi, C | 1 |
Paschou, SA | 1 |
Voziki, E | 1 |
Goulis, DG | 1 |
Stone, LS | 1 |
German, JP | 1 |
Kitto, KF | 1 |
Fairbanks, CA | 1 |
Wilcox, GL | 1 |
Slawski, BA | 1 |
Cohn, SL | 1 |
Pfeifer, KJ | 1 |
Dutta, S | 1 |
Jaffer, AK | 1 |
Smetana, GW | 1 |
Cegarra-Sanmartin, V | 1 |
Paniagua-Iglesias, P | 1 |
Popova, E | 1 |
de Nadal Clanchet, M | 1 |
Alonso-Coello, P | 1 |
Plou, P | 1 |
Mata Mena, E | 1 |
Fernández-Riveira, C | 1 |
García del Valle, S | 1 |
Tena Blanco, B | 1 |
Sabaté Tenas, S | 1 |
Font Gual, A | 1 |
Maestre Hittinger, ML | 1 |
González Rodríguez, R | 1 |
Willaschek, C | 1 |
Meint, S | 1 |
Rager, K | 1 |
Buchhorn, R | 1 |
Katare, PB | 1 |
Banerjee, SK | 1 |
Schlaich, MP | 1 |
Socratous, F | 1 |
Hennebry, S | 1 |
Eikelis, N | 1 |
Lambert, EA | 1 |
Straznicky, N | 1 |
Esler, MD | 1 |
Lambert, GW | 1 |
Cortese, S | 1 |
Holtmann, M | 1 |
Banaschewski, T | 1 |
Buitelaar, J | 1 |
Coghill, D | 1 |
Danckaerts, M | 1 |
Dittmann, RW | 1 |
Graham, J | 1 |
Taylor, E | 1 |
Sergeant, J | 1 |
Wallace, AW | 1 |
Galindez, D | 1 |
Salahieh, A | 1 |
Layug, EL | 1 |
Lazo, EA | 1 |
Haratonik, KA | 1 |
Boisvert, DM | 1 |
Kardatzke, D | 1 |
Strain, JJ | 1 |
Liebowitz, MR | 1 |
Klein, DF | 1 |
Hayduk, K | 1 |
Halawa, B | 1 |
Zarifis, J | 1 |
Lip, GY | 1 |
Ferner, RE | 1 |
Conner, CS | 1 |
Watanabe, AS | 1 |
Guthrie, GP | 1 |
Genest, J | 1 |
Kuchel, O | 1 |
Flacke, JW | 1 |
Ogawa, N | 1 |
Asanuma, M | 1 |
Hirata, H | 1 |
Ota, Z | 1 |
Yamawaki, Y | 1 |
Yamamoto, M | 1 |
Pavlov, AA | 1 |
Rykin, BA | 1 |
Vanholder, R | 1 |
Lamiere, N | 1 |
Ringoir, S | 1 |
Houston, MC | 1 |
Almeyda, J | 1 |
Levantine, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Impact of Renal SympAthetic DenerVation on Chronic HypErtension[NCT01628198] | 38 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to recommendation by the study's DSMB due to insufficient data to determine efficacy.) | |||
Renal Sympathetic Denervation for the Management of Chronic Hypertension[NCT01628172] | 96 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
Therapeutic Use of Repetitive Transcranial Magnetic Stimulation (rTMS) in Pediatric Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Cohorts (ADHD): a Randomized, Sham-controlled Study.[NCT06069323] | 80 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | |||
Hemodynamic Effect of Intrathecal Clonidine in Hypertensive Subjects: A Pilot Study to Assess Its Effectiveness in Hypertensive Subjects With Poor Blood Pressure Control (Phase II)[NCT01297335] | Phase 2 | 10 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The change in diastolic blood pressure as measured by 24 hour ambulatory monitoring at 6 months as compared to from baseline. (NCT01628198)
Timeframe: baseline and 6 months
Intervention | mmHg mean change (Mean) |
---|---|
Renal Denervation Group | -5.5 |
The change in systolic blood pressure as measured by 24 hour ambulatory monitoring at 6 months as compared to from baseline. (NCT01628198)
Timeframe: baseline and 6 months
Intervention | mmHg (Mean) |
---|---|
Renal Denervation Group | -10.2 |
The total number of anti-hypertensive medications at baseline, 6 months, and 12 months (NCT01628198)
Timeframe: Baseline, 6 months, 12 months
Intervention | medications (Mean) | ||
---|---|---|---|
Baseline | 6 months | 12 months | |
Renal Denervation Group | 5.37 | 4.79 | 4.64 |
A blood urea nitrogen (BUN) test measures the amount of nitrogen in blood that comes from the waste product urea. Urea is made when protein is broken down in the body. Urea is made in the liver and passed out in the urine. (NCT01628198)
Timeframe: baseline, 6 months, 12 months
Intervention | mg/dL (Mean) | ||
---|---|---|---|
Baseline | 6 months | 12 months | |
Renal Denervation Group | 20.82 | 22.15 | 23.11 |
Creatinine measures the level of the waste product in the body. The amount of creatinine in the blood depends partly on the amount of muscle tissue you have. Men generally have higher creatinine levels than women.Normal levels of creatinine in the blood are approximately 0.6 to 1.2 milligrams (mg) per deciliter (dL) in adult males and 0.5 to 1.1 milligrams per deciliter in adult females. High levels of creatinine indicates kidney impairment. (NCT01628198)
Timeframe: baseline, 6 months, 12 months
Intervention | mg/dl (Mean) | ||
---|---|---|---|
Baseline | 6 months | 12 months | |
Renal Denervation Group | 1.6 | 1.68 | 2.03 |
Different time points office diastolic blood pressure measurements (NCT01628198)
Timeframe: baseline, 6 month, 12 months
Intervention | mm Hg (Mean) | ||
---|---|---|---|
Baseline | 6 months | 12 months | |
Renal Denervation Group | 87.06 | 86.93 | 87.75 |
Different time points office systolic blood pressure measurements (NCT01628198)
Timeframe: baseline, 6 month, 12 months
Intervention | mm Hg (Mean) | ||
---|---|---|---|
Baseline | 6 months | 12 months | |
Renal Denervation Group | 156.86 | 151.19 | 158.45 |
Renal artery blood flow as measured by Renal Aortic Ratio (RAR) = Peak systolic Velocity renal artery / Peak Systolic Velocity Aorta. A >60% stenosis is reported when there is a >3.5:1 Renal to Aortic Ratio. (NCT01628198)
Timeframe: Baseline and 12 months
Intervention | ratio (Mean) | |||
---|---|---|---|---|
Baseline Right RAR | Baseline Left RAR | 12 months Right RAR | 12 months Left RAR | |
Renal Denervation Group | 1.38 | 1.52 | 1.41 | 1.52 |
Dimensions of renal artery, right and left (NCT01628198)
Timeframe: baseline and 12 months
Intervention | mm (Mean) | |||
---|---|---|---|---|
Baseline R Kidney | Baseline L Kidney | 12 months R Kidney | 12 months L Kidney | |
Renal Denervation Group | 11.43 | 11.68 | 11.26 | 11.39 |
Renal artery blood flow as measured by Resistive Index. RI = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity. the normal value is ~ 0.60, with 0.70 being around the upper limits of normal (NCT01628198)
Timeframe: Baseline and 12 months
Intervention | index (Mean) | |||
---|---|---|---|---|
Baseline Right RI | Baseline Left RI | 12 months Right RI | 12 months Left RI | |
Renal Denervation Group | 0.67 | 0.72 | 0.72 | 0.72 |
"Subjects baseline blood pressure (systolic blood pressure (SBP), and diastolic blood pressure (DBP)), and blood pressures after clonidine injection was compared against baseline to assess efficacy of clonidine in refractory hypertensive subjects. Subject's blood pressure was monitored continuously after intrathecal injection of clonidine until subjects blood pressure nadir and return to pre clonidine injection level. The mean value reported below are the average changes in blood pressure from baseline (pre clonidine injection) in both SBP and DBP during post clonidine injection blood pressure monitoring for 4 hours.~Blood pressure measurements were collected every 10 minutes for first hour after injection, and every 15 minutes after the first hour, up to 4 hours were averaged to report the change from baseline." (NCT01297335)
Timeframe: Baseline, Every 10 Minutes for first hour after clonidine injection, and every 15 minutes after first hour, until 4 hours after clonidine injection
Intervention | mm Hg (Mean) | |
---|---|---|
Change in mean SBP after clonidine injection | Change in DBP after clonidine injection | |
Intrathecal Clonidine | 79 | 37 |
Subjects were asked to rate severity of two of the most common side effects of clonidine, sedation and sensation of dry mouth, at pre and post (1 hour after) intrathecal administration of clonidine. The mean changes between pre and post injection VAS ratings of sedation and sensation of dry mouth are reported below. The VAS scale ranges from 1 to 10 cm, with higher values indicating higher level of sedation and higher level of dry mouth. (NCT01297335)
Timeframe: Before clonidine injection (Baseline), and at 1 hour after clonidine injection.
Intervention | cm (Mean) | |
---|---|---|
Change in level of sedation | Change in sensation of dry mouth | |
Intrathecal Clonidine | 3.36 | 3.47 |
Likert scale is 11 point digital pain rating system that asks subjects to rate their pain from 0 to 10. Rating of 0 means no pain at all, and in increasing order, 10 would mean worst pain imaginable/ unbearable pain. (NCT01297335)
Timeframe: Pre-dose and 1 hour post injection.
Intervention | units on a scale (Mean) | |
---|---|---|
Pre-injection average Likert score | Post-injection average Likert score | |
Intrathecal Clonidine | 6.5 | 3.6 |
14 reviews available for clonidine and Cardiovascular Diseases
Article | Year |
---|---|
Non-Hormonal Replacement Therapy Regimens: Do they have an Effect on Cardiovascular Risk?
Topics: Cardiovascular Diseases; Clonidine; Female; Gabapentin; Humans; Menopause; Phytoestrogens; Pregabali | 2019 |
Perioperative cardiovascular medicine: an update of the literature 2013-2014.
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiovascular Diseases; Clonidine; Heart Arrest; Humans; P | 2014 |
Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario.
Topics: Allopurinol; Aspirin; Bromocriptine; Cardiovascular Diseases; Clonidine; Colesevelam Hydrochloride; | 2016 |
Sympathetic activation in chronic renal failure.
Topics: Animals; Cardiovascular Diseases; Catecholamines; Clonidine; Debrisoquin; Disease Models, Animal; Ef | 2009 |
Sympathetic activation in chronic renal failure.
Topics: Animals; Cardiovascular Diseases; Catecholamines; Clonidine; Debrisoquin; Disease Models, Animal; Ef | 2009 |
Sympathetic activation in chronic renal failure.
Topics: Animals; Cardiovascular Diseases; Catecholamines; Clonidine; Debrisoquin; Disease Models, Animal; Ef | 2009 |
Sympathetic activation in chronic renal failure.
Topics: Animals; Cardiovascular Diseases; Catecholamines; Clonidine; Debrisoquin; Disease Models, Animal; Ef | 2009 |
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure | 2013 |
Anxiety and panic attacks in the medically ill.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; | 1981 |
[Complications associated with sudden withdrawal of various drugs used in the treatment of cardiovascular diseases].
Topics: Cardiovascular Diseases; Clonidine; Guanethidine; Humans; Nitroglycerin; Nitroprusside; Propranolol; | 1981 |
Poisoning with anti-hypertensive drugs: methyldopa and clonidine.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Central Nervous System Diseases; Clonidine; Drug O | 1995 |
Clonidine overdose: a review.
Topics: Adolescent; Adult; Cardiovascular Diseases; Child, Preschool; Clonidine; Coma; Female; Humans; Hypot | 1979 |
Renin and the therapy of hypertension.
Topics: Animals; Antihypertensive Agents; Cardiovascular Diseases; Clonidine; Diazoxide; Diuretics; Dogs; Fe | 1976 |
Alpha 2-adrenergic agonists in cardiovascular anesthesia.
Topics: Adrenergic alpha-Agonists; Anesthesia; Animals; Cardiovascular Diseases; Clonidine; Dogs; Humans; St | 1992 |
Therapeutic effect and complication profile of clonidine-beta-blocker combinations.
Topics: Adrenergic beta-Antagonists; Cardiovascular Diseases; Clonidine; Drug Combinations; Humans; Hyperten | 1988 |
Treatment of hypertensive emergencies and urgencies with oral clonidine loading and titration. A review.
Topics: Blood Pressure; Cardiovascular Diseases; Clonidine; Drug Administration Schedule; Emergencies; Human | 1986 |
Cutaneous reactions to cardiovascular drugs.
Topics: Adrenergic beta-Antagonists; Cardiovascular Diseases; Clonidine; Debrisoquin; Digitalis Glycosides; | 1973 |
3 trials available for clonidine and Cardiovascular Diseases
Article | Year |
---|---|
[Perioperative acetylsalicylic acid and clonidine in noncardiac surgery patients (POISE-2 trial)].
Topics: Adrenergic alpha-2 Receptor Agonists; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clo | 2015 |
Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery.
Topics: Adrenergic alpha-Agonists; Aged; Anesthesia; Arrhythmias, Cardiac; Cardiovascular Diseases; Catechol | 2004 |
Therapeutic effect and complication profile of clonidine-beta-blocker combinations.
Topics: Adrenergic beta-Antagonists; Cardiovascular Diseases; Clonidine; Drug Combinations; Humans; Hyperten | 1988 |
6 other studies available for clonidine and Cardiovascular Diseases
Article | Year |
---|---|
Is GRK2 a new target for cardiovascular disease?
Topics: Cardiovascular Diseases; Clonidine; Diabetes Mellitus; Humans; Hypertension | 2018 |
Morphine and clonidine combination therapy improves therapeutic window in mice: synergy in antinociceptive but not in sedative or cardiovascular effects.
Topics: Analgesics; Animals; Cardiovascular Diseases; Clonidine; Dose-Response Relationship, Drug; Drug Syne | 2014 |
Modified Clonidine Testing for Growth Hormone Stimulation Reveals α2-Adrenoreceptor Sub Sensitivity in Children with Idiopathic Growth Hormone Deficiency.
Topics: Adrenergic alpha-2 Receptor Agonists; Blood Pressure; Body Height; Cardiovascular Diseases; Child; C | 2015 |
[Clonidine: new aspects of a known principle].
Topics: Cardiovascular Diseases; Clonidine; Heart Failure; Humans; Hypertension | 1983 |
Development of a simple spasticity quantification method: effects of tizanidine on spasticity in patients with sequelae of cerebrovascular disease.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clonidine; Female; Humans; Male; Middle Aged; Musc | 1992 |
[Side effects of long-term drug therapy of patients with uncomplicated arterial hypertension in a polyclinic].
Topics: Adolescent; Adult; Antihypertensive Agents; Cardiovascular Diseases; Clonidine; Dose-Response Relati | 1991 |